Imaging Inflammation
To determine the relationship between inflammation, cognitive impairment, and amyloid burden in elderly subjects with different clinical and biomarker profiles of Alzheimer's disease (AD). Participants will undergo amyloid PET imaging with 18F-Florbetaben, 11C-PBR28 PET imaging to measure the 18 kDa translocator protein (a marker of inflammation), and an optional lumbar puncture performed to measure CSF concentrations of amyloid,tau, phospho-tau, and inflammatory markers.
15 amyloid-positive elders with impairment, 15 amyloid-positive elders with normal cognition, 15 amyloid-negative elders with impairment, and 15 amyloid-negative elders with normal cognition.
100
injection of radioactive tracers, Invasive lumbar puncture, discomfort, recovery time in clinic to decrease risk of spinal fluid leakage
PET technician, PET scanner, dyes, physician who can preform a lumbar puncture as well as a clinic designed for this testing, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g., mass spectrometer, protein assay kit, ELISA, or western blot)
William Charles Kreisl, Columbia University; National Institute on Aging (NIA)
“Imaging Inflammation in Alzheimer's Disease.” ClinicalTrials.gov. Accessed October 10, 2019. https://clinicaltrials.gov/ct2/show/NCT02831283?term=biomarker&recrs=abdf&cond=Alzheimer+Disease&draw=3&rank=21